Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05224804
Other study ID # Pharmacovigilance
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 1, 2020
Est. completion date September 10, 2021

Study information

Verified date January 2022
Source Fayoum University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The present study has assessed the knowledge, attitude and practice of ADRs reporting among pharmacists, and the perceived factors that may influence reporting.


Description:

The practice and science of pharmacovigilance is described as the gathering, identification, monitoring, assessment, and prevention of adverse medication effects using pharmaceutical products. The term "pharmacovigilance" comes from the Greek words pharmakon (drug) and vigilare (vigilance) (monitor or keep an eye on). Pharmacovigilance (PV) is defined by the World Health Organization (WHO) as "the science and practices relating to the detection, assessment, understanding, and prevention of adverse effects or other drug-related problems". PV assesses the risk-benefit profile of medicines in order to improve patient safety. As a result, adverse drug reaction (ADR) reporting is the bedrock of any PV system, and early detection and reporting of ADRs to regional or national drug-regulatory bodies is important. ADRs are defined by the World Health Organization as an unpleasant and unexpected response to a medicine that occurs at levels usually employed in man for the prevention, diagnosis, or therapy of disease, or for the alteration of physiological function". Adverse drug reactions (ADRs) are major public health issues that have been linked to longer hospital stays and higher therapeutic costs. According to recent systematic reviews and meta-analyses of observational research, the rate of hospital admissions linked to ADRs is between 3-5 percent. A number of factors have been linked to HCPs, particularly pharmacists, reporting ADRs. Several studies have indicated reasons for not reporting observed ADRs, and pharmacists have been polled to determine the most important facilitators and barriers to spontaneous reporting. The seven deadly sins were coined by Inman and later defined by Lopez-Gonzalez et al., into professional and personal traits, as well as knowledge and attitudes toward reporting. Pharmacists from throughout the world have highlighted a number of barriers to reporting ADRs, including a lack of time, the inability to correlate an adverse event (AE) to a specific medicine, and the absence of readily available reporting forms . It has also emphasized the necessity of educational measures to encourage ADR reporting, such as awareness lectures and workshops. Egypt joined the WHO International Program for Drug Monitoring in 2001, but no concrete actions were done until 2009, when the Egyptian Pharmacovigilance Center was established (EPVC). Receiving ADR reports, detecting safety signals, sending frequent newsletters with pharmacovigilance (PV)-related updates, and conducting awareness training are only a few of EPVC's responsibilities.


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date September 10, 2021
Est. primary completion date September 10, 2021
Accepts healthy volunteers
Gender All
Age group 20 Years to 50 Years
Eligibility Inclusion Criteria: - Pharmacist graduates Exclusion Criteria: undergrauate pharmacist -

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
knwoledge
Knowledge and Attitudes about ADRs Reporting

Locations

Country Name City State
Egypt Marwa Kamal Ahmed Tolba Fayoum

Sponsors (1)

Lead Sponsor Collaborator
Fayoum University

Country where clinical trial is conducted

Egypt, 

References & Publications (1)

Beninger P. Pharmacovigilance: An Overview. Clin Ther. 2018 Dec;40(12):1991-2004. doi: 10.1016/j.clinthera.2018.07.012. Epub 2018 Aug 17. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Pharmacists' Knowledge and Attitudes about ADRs Reporting and Pharmacovigilance Practice in Egyptian Hospitals The majority of pharmacists was knowledgeable about pharmacovigilance and had a favourable attitude toward ADR reporting. There are several variables that discourage pharmacists from reporting suspected ADRs, including the belief that there is no advantage to reporting, the presence of administrative barriers, the lack of availability of the ADR reporting form, and the lack of encouragement from hospital administration. 1 year and 4 month to collect data.
See also
  Status Clinical Trial Phase
Suspended NCT02559960 - Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
Completed NCT01946919 - Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study
Recruiting NCT04154553 - Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions or Therapy Failure
Completed NCT01732302 - Educational Intervention to Reduce Drug-related Hospitalizations in Elderly Primary Health Care Patients N/A
Completed NCT02297126 - A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program N/A
Completed NCT03093818 - PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions N/A
Not yet recruiting NCT04568668 - Evaluating ActionADE in Reducing Adverse Drug Reactions N/A
Recruiting NCT02012504 - Antidepressant Monotherapy on Depressive and Anxiety Symptom in Chinese Patients Phase 0
Completed NCT01872520 - Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan A Real World Study N/A
Completed NCT01467050 - Prevention of Adverse Drug Events (ADEs) in Hospitalised Older Patients Phase 4
Completed NCT01679964 - Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study Phase 4
Completed NCT02094638 - Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study N/A
Recruiting NCT01906710 - the Pharmacy Intervention Team Hospital-based (PITH) for People Study: Effect on Clinical and Economic Outcomes N/A
Completed NCT02888834 - Serious Adverse Drug Reaction and Their Preventability N/A
Completed NCT02838212 - Adverse Drug Reactions With Fatal Outcome N/A
Completed NCT02159209 - The Drug Induced Renal Injury Consortium N/A
Completed NCT02134587 - Educational Intervention in Pharmacovigilance for Hospital Health Professionals N/A
Completed NCT04553107 - Reducing Costs by Deprescribing Medications N/A
Recruiting NCT06219720 - The Texas Interprofessional Pharmacogenomics (IPGx)
Recruiting NCT05508763 - Personalised Therapeutics @LUMC